Introduction {#section4-2050313X19838739}
============

Carcinomas of unknown primary (CUPs) represent an uncommon cancer diagnosis defined by the US National Cancer Institute^[@bibr1-2050313X19838739]^ as "... a rare disease in which malignant (cancer) cells are found in the body but the place the cancer began is not known."

We report the case of a 56-year-old female who presented to medical attention with palpable axillary adenopathy. Biopsy confirmed a poorly differentiated adenocarcinoma. We describe the diagnostic evaluation, treatment, and durable clinical response of this patient through the use of laboratory-guided therapy.

Case {#section5-2050313X19838739}
====

A 56-year-old female patient presented to her gynecologist in February 2013 with a palpable lymph node in the right axilla. Bilateral mammograms and blood tumor markers were obtained. Mammograms identified bilateral lymphadenopathy. With the exception of an elevated carbohydrate antigen CA19-9, all other tumor markers were normal. Magnetic resonance imaging (MRI) of the abdomen and computed tomography (CT) confirmed bilateral axillary nodes, multiple liver lesions, retroperitoneal lymph, and multiple bone lesions. Upper gastrointestinal endoscopy and colonoscopy were negative.

A Positron Emission Tomography Scan (PET-CT) obtained revealed neoplastic disease with high metabolic activity in cervical lymph nodes as well as in mediastinal, mesenteric, and retroperitoneal areas. The lesions in the liver were also identified. High metabolic uptake was also observed in sclerotic bone lesions in the thoracolumbar spine. Brain MRI was negative for central nervous system lesions ([Supplemental Appendix 1](https://journals.sagepub.com/doi/suppl/10.1177/2050313X19838739)).

Histopathology of the axillary and liver nodule confirmed poorly differentiated invasive carcinoma ([Figure 1](#fig1-2050313X19838739){ref-type="fig"}). Immunohistochemistry was negative for estrogen and progesterone receptors, Human Epidermal Growth Factor Receptor 2, chromogranin, and synaptophysin, and positive for p63, pan-cytokeratin, and CD56.

![Histopathology of the axillary nodule.\
Poorly differentiated invasive carcinoma, with intense nuclear pleomorphism and high mitotic activity.](10.1177_2050313X19838739-fig1){#fig1-2050313X19838739}

Capecitabine 3000 mg daily in divided oral dose was initiated. An additional expanded immunohistochemical (IHC) profile was negative for smooth muscle actin, GCDFP15, epithelial antigen, CD45, COX-2, Platelet-derived growth factor receptor, somatostatin, C-kit, Fibroblast Growth Factor-basic, vascular endothelial growth factor, vascular endothelial growth factor receptor (VEGFR), and CD-20, and positive for vimentin, CD117, p21, Ras, B cell lymphoma 2, Excision Repair Cross-Complementation Group 1, and weak expression of peroxisome proliferator-activated receptor-gamma.

A portion of the tumor was submitted for Ex Vivo Analysis of Programmed Cell Death (EVA/PCD). The techniques have been the subject of prior review.^[@bibr2-2050313X19838739],[@bibr3-2050313X19838739]^ This analysis revealed activity for paclitaxel and vinorelbine, with intermediate activity for fluoropyrimidines, carboplatin, irinotecan, and gemcitabine. A strong cytotoxic signal was observed for sorafenib. Despite the high degree of activity for sorafenib, erlotinib, pazopanib, and imatinib revealed no activity.

Following four cycles of oral capecitabine, the patient, who had previously been asymptomatic, now presented with paresis and spasms in the right lower limb. MRI of the cervical spine confirmed bony destruction of the entire C7 vertebral body causing dural compression. Radiotherapy was immediately initiated. Then, a new PET-CT in June 2013 revealed massive disease progression ([Supplemental Appendix 2](https://journals.sagepub.com/doi/suppl/10.1177/2050313X19838739)). Based upon the results of the ex vivo analysis, we initiated a treatment regimen consisting of oral sorafenib at 200 mg bid, combined with Vinorelbine at 25 mg/m^2^ and Paclitaxel at 80 mg/m^2^, both given weekly.

After 2 months of treatment, PET-CT obtained on 21 August 2013 confirmed significant reduction in the size and metabolic activity of the lesions in the liver as well as in the cervical, supraclavicular, axillary, retroperitoneal, and mediastinal lymph nodes. In addition, the multiple subcutaneous, peritoneal, pleural, and pulmonary nodules as well as the pleural effusion had all disappeared. The bone lesions had also decreased revealing absence of metabolic activity ([Figure 2](#fig2-2050313X19838739){ref-type="fig"}).

![PET-CT, June and August 2013.\
Important metabolic response within 3 months of cancer treatment.](10.1177_2050313X19838739-fig2){#fig2-2050313X19838739}

The patient remained on the sorafenib/vinorelbine/paclitaxel regimen for over 1 year with continued response and good tolerance. After 1 year of treatment, PET-CT obtained on August 2014 evidences multiple new hepatic lesions. Based on ex vivo analysis, we initiated treatment with carboplatin area under curve 2 and irinotecan 80 mg/m^2^ weekly. Scheme maintained until December 2014, when control PET-CT showed progression of liver lesions besides the appearance of pulmonary nodules. Then we initiated new treatment with gemcitabine (800 mg/m^2^) 2 weeks in a row every 3 weeks. Despite of treatment, in March 2015, new hepatic lesions are evidenced in PET-CT. We started (fluorouracil, 2400 mg/m^2^; leucovorin, 400 mg/m^2^; and oxaliplatin, 85 mg/m^2^ q2w (FOLFOX regimen). After a further progression in July 2015 ([Supplemental Appendix 3](https://journals.sagepub.com/doi/suppl/10.1177/2050313X19838739)), the patient died in August 2015.

Discussion {#section6-2050313X19838739}
==========

The incidence of CUP ranges from 3% to 5% in demographic surveys, with the majority of the cases having a poor prognosis. The published literature has shown an average survival of 7 to 9 months in cases of metastatic CUP disease.^[@bibr4-2050313X19838739],[@bibr5-2050313X19838739]^

In the 1970s, the diagnosis of CUP could often only be confirmed at the time of autopsy.^[@bibr6-2050313X19838739]^ Nowadays, this diagnosis is only entertained if no primary is identified following full clinical examination, including both pelvic and rectal, complete blood counts, biochemical tests, immunohistochemistry, and body imaging by CT and MRI.^[@bibr4-2050313X19838739],[@bibr7-2050313X19838739]^ The use of PET-CT is not formally recommended, although some studies support its use.^[@bibr8-2050313X19838739]^

It is hypothesized that CUP tumors develop the capacity to invade vascular and lymphatic channels and to generate tumor metastases before the primary lesion has grown to a dimension adequate to permit its identification. The typical spectrum observed is early dissemination in asymptomatic patients, often with the clinical absence of constitutional symptoms of the primary tumor. Patterns of early dissemination have been reported in previous studies.^[@bibr9-2050313X19838739],[@bibr10-2050313X19838739]^

The treatment indicated by consensus is chemotherapy based on histology, determined by histopathology and immunohistochemistry. The use of molecular markers, genetic profiling platforms, and personalized medicine is under active investigation.^[@bibr5-2050313X19838739],[@bibr11-2050313X19838739],[@bibr12-2050313X19838739]^

Immunohistochemistry can be extremely useful in the diagnosis but often fail to elucidate the primary. Molecular analyses designed to select treatments based upon genomic profiles are under investigation. Due to different tumor susceptibility profiles, many experts believe that conventional empirical chemotherapy should only be used in cases when there are no tumor samples available.^[@bibr12-2050313X19838739],[@bibr13-2050313X19838739]^

When the patient progressed following chemotherapy, she received radiation to control symptomatic disease. The subsequent choice of treatment was based upon the results of the EVA/PCD functional analysis that identified activity for sorafenib. The activity, however, was unique to sorafenib, as the related pazopanib as well as imatinib and erlotinib revealed no activity.

Sorafenib is a diaryl ether, tyrosine kinase inhibitor active against Raf, PDGFb, VEGFR-2,3, and c-KIT with cross-reactivity with fms like tyrosine kinase 3 and RET that is approved in the United States for the treatment of renal cell, hepatocellular, and thyroid cancer. What distinguishes Sorafenib from all of the other drugs evaluated against the patient's tumor is its unique capacity to induce ferroptosis. Ferroptosis, originally described by Dixon et al.,^[@bibr14-2050313X19838739]^ is a form of non-apoptotic programmed cell death associated with the inhibition of System Xc, a cell surface Na^+^-independent cysteine--glutamate antiporter. Structure activity analyses have subsequently identified sorafenib as a potent inhibitor of Xc, capable of inducing ferroptotic cell death.^[@bibr15-2050313X19838739]^

The subsequent clinical benefit following treatment with this agent associated with chemotherapy could support a role of ferroptosis in this patient's clinical response. At the time of this writing, there are no molecular signatures for ferroptosis rendering interrogation of tissue blocks impossible. The role of functional analyses, like the EVA/PCD assay, for the selection of chemotherapy drugs and combinations are under investigation.^[@bibr16-2050313X19838739]^

Conclusion {#section7-2050313X19838739}
==========

Cases of CUP continue to present considerable clinical challenges for practicing oncologists. This patient's outcome represents an excellent response to a novel treatment regimen that was chosen based upon the patient's own unique drug sensitivity profile. There is an urgent need to develop more targeted and personalized approaches for patients with complicated cases of CUP.
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